This suggests that in cancer patients, blocking anti-GARP:TGF-β1 mAbs that are unable to bind FcγRs would be as efficient and probably safer than effector-competent formats, because they would not cause Treg depletion and potential subsequent auto-immune adverse events, nor kill any other GARP-expressing cells in cutaneous melanoma metastases and non-cancerous tissues. The gene discussed is TGFB1; the disease is cancer.